Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

terminated133%
completed133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
terminated

Pregnancy Outcomes and Maternal Insulin Sensitivity

NCT04315545
unknownnot_applicable

Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations

NCT02023489
completedphase_3

US Inhaled Insulin Dose Titration Study

NCT00246623

Clinical Trials (3)

Showing 3 of 3 trials
NCT04315545

Pregnancy Outcomes and Maternal Insulin Sensitivity

Terminated
NCT02023489Not Applicable

Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations

Unknown
NCT00246623Phase 3

US Inhaled Insulin Dose Titration Study

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3